{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:51:43Z","timestamp":1787237503212,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T00:00:00Z","timestamp":1560384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1007\/s12094-019-02153-4","type":"journal-article","created":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T12:03:44Z","timestamp":1560427424000},"page":"612-615","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Outpatient management of incidental pulmonary embolism in cancer patient"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-8249","authenticated-orcid":false,"given":"Andr\u00e9s J.","family":"Mu\u00f1oz Mart\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena Carmen","family":"Ruiz Zamorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Carmen","family":"Vi\u00f1uela Ben\u00e9itez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ortega Mor\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Garc\u00eda P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Mart\u00edn Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,13]]},"reference":[{"key":"2153_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","volume":"149","author":"C Kearon","year":"2016","unstructured":"Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315\u201352.","journal-title":"Chest"},{"issue":"3033\u201369","key":"2153_CR2","first-page":"3069a","volume":"35","author":"SV Konstantinides","year":"2014","unstructured":"Konstantinides SV, Torbicki A, Agnelli G, Danchin N, Fitzmaurice D, Gali\u00e8 N, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35(3033\u201369):3069a\u2013.","journal-title":"Eur Heart J."},{"key":"2153_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/1076029616674827","volume":"24","author":"PD Stein","year":"2018","unstructured":"Stein PD, Matta F, Hughes MJ. National trends in home treatment of acute pulmonary embolism. Clin Appl Thromb Hemost. 2018;24:115\u201321.","journal-title":"Clin Appl Thromb Hemost."},{"key":"2153_CR4","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.amjmed.2016.03.035","volume":"129","author":"PD Stein","year":"2016","unstructured":"Stein PD, Matta F, Hughes PG, Hourmouzis ZN, Hourmouzis NP, White RM, et al. Home treatment of pulmonary embolism in the era of novel oral anticoagulants. Am J Med. 2016;129:974\u20137.","journal-title":"Am J Med"},{"key":"2153_CR5","doi-asserted-by":"crossref","unstructured":"Kraaijpoel N, Bleker SM, Meyer G, Mah\u00e9 I, Mu\u00f1oz A, et al. Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: an international prospective cohort study. J Clin Oncol. 2019:JCO1801977.","DOI":"10.1200\/JCO.18.01977"},{"key":"2153_CR6","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1200\/JCO.2010.34.0984","volume":"29","author":"PL den Exter","year":"2011","unstructured":"den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol. 2011;29:2405\u20139.","journal-title":"J Clin Oncol."},{"key":"2153_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/07357907.2011.633295","volume":"30","author":"A Palla","year":"2012","unstructured":"Palla A, Rossi G, Falaschi F, Marconi L, Pistolesi M, Prandoni P. Is incidentally detected pulmonary embolism in cancer patients less severe? A case-control study. Cancer Invest. 2012;30:131\u20134.","journal-title":"Cancer Invest"},{"key":"2153_CR8","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1200\/JCO.2013.49.1118","volume":"31","author":"GH Lyman","year":"2013","unstructured":"Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31:2189\u2013204.","journal-title":"J Clin Oncol."},{"key":"2153_CR9","doi-asserted-by":"publisher","first-page":"e452","DOI":"10.1016\/S1470-2045(16)30369-2","volume":"17","author":"D Farge","year":"2016","unstructured":"Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17:e452\u2013e466466.","journal-title":"Lancet Oncol."},{"key":"2153_CR10","doi-asserted-by":"crossref","unstructured":"Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-4.","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"2153_CR11","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1038\/bjc.2017.48","volume":"116","author":"A Carmona-Bayonas","year":"2017","unstructured":"Carmona-Bayonas A, Jim\u00e9nez-Fonseca P, Font C, Fenoy F, Otero R, Beato C, et al. Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: the EPIPHANY Index. Br J Cancer. 2017;116:994\u20131001.","journal-title":"Br J Cancer."},{"key":"2153_CR12","doi-asserted-by":"publisher","first-page":"3601","DOI":"10.1007\/s00520-018-4235-9","volume":"26","author":"S Ahn","year":"2018","unstructured":"Ahn S, Cooksley T, Banala S, Buffardi L, Rice TW. Validation of the EPIPHANY index for predicting risk of serious complications in cancer patients with incidental pulmonary embolism. Support Care Cancer. 2018;26:3601\u20137.","journal-title":"Support Care Cancer."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02153-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-019-02153-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02153-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T14:47:54Z","timestamp":1663685274000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-019-02153-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,13]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["2153"],"URL":"https:\/\/doi.org\/10.1007\/s12094-019-02153-4","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"value":"1699-048X","type":"print"},{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,13]]},"assertion":[{"value":"12 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Andr\u00e9s J. Mu\u00f1oz Martin: Dr. Mu\u00f1oz has received speakers\u2019 honoraria or honoraria for participation in Advisory Boards from Sanofi, Celgene, Leo Pharma, Daiichi Sankyo, Pzifer-BMS, Rovi, Celgene, Shire, Astra-Zeneca and Medscape and research grants from Sanofi and Leo Pharma. Magdalena Carmen Ruiz Zamorano, Mar\u00eda Carmen Vi\u00f1uela Ben\u00e9itez, Laura Ortega Mor\u00e1n and \u00c1ngela Garc\u00eda P\u00e9rez declare that they have no conflict of interest. Dr. Miguel Mart\u00edn Jim\u00e9nez: Dr. Martin has received speakers\u2019 honoraria or honoraria for participation in Advisory Boards from AstraZeneca, Novartis, Roche-Genentech, Pfizer Glaxo, Pharmamar, Taiho Oncology and Lilly, and research grants from Novartis and Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was approved by the Ethics Committee of Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain. The study has been approved by the appropriate institutional and\/or national research ethics committee and has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}